about
Meta-analysis of benzodiazepine use in the treatment of insomniaHigh dose triazolam and anterograde amnesiaEvaluation of an easy, cost-effective strategy for cutting benzodiazepine use in general practiceThe use of benzodiazepines among regular amphetamine users.Benzodiazepines as a social problem: the case of halcion.Hallucinations after a therapeutic dose of benzodiazepine hypnotics with co-administration of erythromycin.Effect of sleep apnea on cognition and mood.Safety of zaleplon in the treatment of insomnia.The condition of insomnia: etiopathogenetic considerations and their impact on treatment practices.Managing insomnia: an overview of insomnia and pharmacologic treatment strategies in use and on the horizon.Neuropsychiatric implications of thyroid hormone and benzodiazepine interactions.Geriatric psychopharmacology. A primary care challenge.Triazolam. As safe as other benzodiazepines.Short acting benzodiazepines.Acute performance-impairing and subject-rated effects of triazolam and temazepam, alone and in combination with ethanol, in humans.[Opinion: the case-scandal of triazolam]Effect of flunitrazepam on sleep and memory.Randomized, double blind trial of zolpidem 10 mg versus triazolam 0.25 mg for treatment of insomnia in general practice.Pilot controlled double-blind study of the hypnotic effects of zolpidem in patients with chronic 'learned' insomnia: psychometric and polysomnographic evaluation.South Korean geriatrics on Beers Criteria medications at risk of adverse drug events.Randomised controlled trial of two brief interventions against long-term benzodiazepine use: outcome of intervention
P2860
Q24534981-096E0197-0707-4407-B545-256474AC5288Q28316625-8FBB6378-0472-4848-82D2-3F8D2AC267DAQ34052709-EC0DAB58-E2A2-4D39-9A52-1F7E78054252Q34319245-8CE9391D-EF06-4DCC-A1EB-2D3D1646C553Q34395895-4A0D9FB6-E732-4818-A47E-22C936514326Q34414908-9038BB7D-EAC8-4ECB-A20D-D3087A2E5DCCQ34455375-8464D094-3A9C-429F-928E-376315B9779EQ34615602-53AAF747-11D1-4C33-BA30-1E1BCA7F46E2Q36272537-0FC3BEF5-F169-4B08-AAD1-17CCC5C1E4BDQ37450164-29F37C1E-4529-4832-BF32-89A8CB73AB3BQ40852689-37D819EF-7E67-43A2-BAD2-E89667FBE990Q40882817-98B3056F-7D06-4400-924C-30DBCA149B47Q43085946-6017FC03-4063-429E-AD02-BA18B0FF011EQ43154067-2BA2AB9A-E59C-4882-9A76-AF13171E4F45Q43956670-51516417-EC35-4DAB-AF63-EB5ABD90D29CQ45769766-DC1FF629-2871-4B1F-A66D-E882A618C5DFQ48792803-7A008CD0-69B0-4F1C-B44A-2B6C39857B56Q48842857-5B2A6BD6-09D0-4D53-906C-F82025D9F72EQ48859510-C534804A-D26C-45C6-9EAA-1C7B62326A4BQ55419661-6AB7B592-E2FE-4E6C-A859-E73B1E8C8572Q56039692-474BBA5E-9AB7-4D34-B11F-3DCF9F8774A6
P2860
description
1991 nî lūn-bûn
@nan
1991 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
Next-day memory impairment with triazolam use
@ast
Next-day memory impairment with triazolam use
@en
Next-day memory impairment with triazolam use
@nl
type
label
Next-day memory impairment with triazolam use
@ast
Next-day memory impairment with triazolam use
@en
Next-day memory impairment with triazolam use
@nl
prefLabel
Next-day memory impairment with triazolam use
@ast
Next-day memory impairment with triazolam use
@en
Next-day memory impairment with triazolam use
@nl
P2093
P1433
P1476
Next-day memory impairment with triazolam use
@en
P2093
A N Vgontzas
E O Bixler
R L Manfredi
P304
P356
10.1016/0140-6736(91)92524-6
P407
P577
1991-04-06T00:00:00Z